How helpful are the European AIDS Clinical Society cognitive screening questions in predicting cognitive impairment in an aging, well-treated HIV-positive population?
HIV and aging
neurocognitive impairment
neuropsychological testing
predictive values
screening
Journal
HIV medicine
ISSN: 1468-1293
Titre abrégé: HIV Med
Pays: England
ID NLM: 100897392
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
accepted:
31
10
2019
pubmed:
29
12
2019
medline:
28
9
2021
entrez:
29
12
2019
Statut:
ppublish
Résumé
Diagnosing neurocognitive impairment (NCI) in HIV infection requires time-consuming neuropsychological assessment. Screening tools are needed to identify when neuropsychological referral is indicated. We examined the positive and negative predictive values (PPVs and NPVs, respectively) of the three European AIDS Clinical Society (EACS) screening questions in identifying NCI. The Neurocognitive Assessment in the Metabolic and Aging Cohort (NAMACO) study recruited patients aged ≥45 years enrolled in the Swiss HIV Cohort Study between 1 May 2013 and 30 November 2016. NAMACO participants (1) answered EACS screening questions, (2) underwent standardized neuropsychological assessment and (3) completed self-report forms [Center for Epidemiologic Studies Depression Scale (CES-D)] rating mood. NCI categories were defined using Frascati criteria. PPVs and NPVs of the EACS screening questions in identifying NCI categories were calculated. Of 974 NAMACO participants with complete EACS screening question data, 244 (25.1%) expressed cognitive complaints in answer to at least one EACS screening question, of whom 51.3% had NCI (26.1% HIV-associated and 25.2% related to confounding factors). The PPV and NPV of the EACS screening questions in identifying HIV-associated NCI were 0.35 and 0.7, respectively. Restricting analysis to NCI with functional impairment or related to confounding factors, notably depression, the NPV was 0.90. Expressing cognitive complaints for all three EACS screening questions was significantly associated with depression (P < 0.001). The EACS screening questions had an NPV of 0.7 for excluding patients with HIV-associated NCI as defined by Frascati criteria. The PPV and NPV may improve if NCI diagnoses are based on new criteria.
Identifiants
pubmed: 31883203
doi: 10.1111/hiv.12828
pmc: PMC7216878
doi:
Types de publication
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
342-348Investigateurs
Matthias Cavassini
(M)
Renaud Du Pasquier
(RD)
Mélanie Métral
(M)
Samanta Simioni
(S)
Peter Brugger
(P)
Klemens Gutbrod
(K)
Andreas U Monsch
(AU)
Ursi Kunze
(U)
Marianne Schneitter
(M)
Isaure Nadin
(I)
Severin Früh
(S)
Marc Schwind
(M)
Riccardo Pignatti
(R)
Stefanie Clarke
(S)
Frédéric Assal
(F)
Tobias Derfuss
(T)
Sebastian von Arx
(S)
Günter Eisele
(G)
Leonardo Sacco
(L)
Manuel Bertschi
(M)
Thomas Hundsberger
(T)
Renaud Du Pasquier
(RD)
Alexandra Calmy
(A)
Thanh Doco Lecompte
(T)
Christoph Hauser
(C)
Alexia Cusini
(A)
Rainer Weber
(R)
Helen Kovari
(H)
Barbara Hasse
(B)
Philip Tarr
(P)
Marcel Stoeckle
(M)
Christoph Fux
(C)
Enos Bernasconi
(E)
Caroline Di Benedetto
(C)
Alessandra Bruno
(A)
Patrick Schmid
(P)
Katharine Darling
(K)
Matthias Cavassini
(M)
Alexandra Scherrer
(A)
Alexandra Scherrer
(A)
Yannick Vallet
(Y)
Deolinda Alves
(D)
Isabella Locatelli
(I)
Laurent Decosterd
(L)
Cristina Granziera
(C)
Gunnar Krueger
(G)
Reto Meuli
(R)
Maria Vargas
(M)
K Aebi-Popp
(K)
A Anagnostopoulos
(A)
M Battegay
(M)
E Bernasconi
(E)
J Böni
(J)
D L Braun
(DL)
H C Bucher
(HC)
A Calmy
(A)
M Cavassini
(M)
A Ciuffi
(A)
G Dollenmaier
(G)
M Egger
(M)
L Elzi
(L)
J Fehr
(J)
J Fellay
(J)
H Furrer
(H)
C A Fux
(CA)
H F Günthard
(HF)
D Haerry
(D)
B Hasse
(B)
H H Hirsch
(HH)
M Hoffmann
(M)
I Hösli
(I)
M Huber
(M)
C R Kahlert
(CR)
L Kaiser
(L)
O Keiser
(O)
T Klimkait
(T)
R D Kouyos
(RD)
H Kovari
(H)
B Ledergerber
(B)
G Martinetti
(G)
B Martinez de Tejada
(B)
C Marzolini
(C)
K J Metzner
(KJ)
N Müller
(N)
D Nicca
(D)
P Paioni
(P)
G Pantaleo
(G)
M Perreau
(M)
A Rauch
(A)
C Rudin
(C)
A U Scherrer
(AU)
P Schmid
(P)
R Speck
(R)
M Stöckle
(M)
P Tarr
(P)
A Trkola
(A)
P Vernazza
(P)
G Wandeler
(G)
R Weber
(R)
S Yerly
(S)
Commentaires et corrections
Type : CommentIn
Type : CommentIn
Informations de copyright
© 2019 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.
Références
HIV Med. 2017 May;18(5):363-369
pubmed: 27785907
J Neurovirol. 2017 Feb;23(1):67-78
pubmed: 27557777
AIDS Patient Care STDS. 2017 Aug;31(8):329-334
pubmed: 28753395
Clin Infect Dis. 2011 Oct;53(8):836-42
pubmed: 21921226
AIDS. 2010 Jun 1;24(9):1243-50
pubmed: 19996937
Int Rev Psychiatry. 2008 Feb;20(1):33-47
pubmed: 18240061
HIV Med. 2010 Nov;11(10):642-9
pubmed: 20456505
HIV Med. 2015 Apr;16 Suppl 1:97-108
pubmed: 25711328
Dement Geriatr Cogn Dis Extra. 2015 Feb 17;5(1):42-50
pubmed: 25852731
Int J Epidemiol. 2010 Oct;39(5):1179-89
pubmed: 19948780
Neurology. 2014 Jun 10;82(23):2055-62
pubmed: 24814848
HIV Med. 2020 Jan;21(1):30-42
pubmed: 31589807
PLoS One. 2018 Apr 11;13(4):e0194760
pubmed: 29641619
AIDS. 2013 Sep 24;27(15):2385-401
pubmed: 23751261
J Neurol. 2017 Aug;264(8):1715-1727
pubmed: 28567537
Neurology. 2007 Oct 30;69(18):1789-99
pubmed: 17914061
Clin Infect Dis. 2016 Sep 1;63(5):687-693
pubmed: 27325690
Neuropsychol Rev. 2009 Jun;19(2):232-49
pubmed: 19455425
J Int Neuropsychol Soc. 2012 Jan;18(1):79-88
pubmed: 22114912